Home › Kidney Cancer (Renal Cell Carcinoma) › NCT06966024
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Key Inclusion Criteria: * Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer * Able to take oral medication * If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements * Adequate organ function and electrolytes Key Exclusion Criteria: * Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812 * Impaired cardiac function * Major surgery within 28 days of the first dose of study drug
About the study
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
What is being tested
- DCC-2812 (drug)
Sponsor: Deciphera Pharmaceuticals, LLC · Participants: 60 · Started: Aug 27, 2025
Contact the study team
- Clinical Team · Phone: 888-724-3274
Official record on ClinicalTrials.gov — NCT06966024
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.